JP2005538046A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005538046A5 JP2005538046A5 JP2004500787A JP2004500787A JP2005538046A5 JP 2005538046 A5 JP2005538046 A5 JP 2005538046A5 JP 2004500787 A JP2004500787 A JP 2004500787A JP 2004500787 A JP2004500787 A JP 2004500787A JP 2005538046 A5 JP2005538046 A5 JP 2005538046A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- domain
- antibody
- monoclonal antibody
- protein according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 claims 34
- 102000037865 fusion proteins Human genes 0.000 claims 34
- 102000002262 Thromboplastin Human genes 0.000 claims 11
- 108010000499 Thromboplastin Proteins 0.000 claims 11
- 102000012607 Thrombomodulin Human genes 0.000 claims 6
- 108010079274 Thrombomodulin Proteins 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 230000035772 mutation Effects 0.000 claims 4
- 101100226846 Strongylocentrotus purpuratus EGF3 gene Proteins 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 206010047249 Venous thrombosis Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000003146 anticoagulant agent Substances 0.000 claims 2
- 229940127219 anticoagulant drug Drugs 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 230000015271 coagulation Effects 0.000 claims 2
- 238000005345 coagulation Methods 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000001415 gene therapy Methods 0.000 claims 2
- 230000028709 inflammatory response Effects 0.000 claims 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 108010054265 Factor VIIa Proteins 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 230000004989 O-glycosylation Effects 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 208000015294 blood coagulation disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229940012414 factor viia Drugs 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000001453 nonthrombogenic effect Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000004792 oxidative damage Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 235000004252 protein component Nutrition 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
- 238000007631 vascular surgery Methods 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37656602P | 2002-05-01 | 2002-05-01 | |
| PCT/US2003/013522 WO2003092602A2 (en) | 2002-05-01 | 2003-04-30 | Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005538046A JP2005538046A (ja) | 2005-12-15 |
| JP2005538046A5 true JP2005538046A5 (enExample) | 2006-06-22 |
| JP4567437B2 JP4567437B2 (ja) | 2010-10-20 |
Family
ID=29401364
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004500787A Expired - Fee Related JP4567437B2 (ja) | 2002-05-01 | 2003-04-30 | 抗凝固剤としての新規組織因子標的化されたトロンボモジュリン融合タンパク質 |
| JP2004501558A Expired - Fee Related JP4460443B2 (ja) | 2002-05-01 | 2003-04-30 | 抗凝固剤としての新規組織因子標的化された抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004501558A Expired - Fee Related JP4460443B2 (ja) | 2002-05-01 | 2003-04-30 | 抗凝固剤としての新規組織因子標的化された抗体 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US7250168B2 (enExample) |
| EP (2) | EP1549341B1 (enExample) |
| JP (2) | JP4567437B2 (enExample) |
| KR (2) | KR101013697B1 (enExample) |
| CN (2) | CN100412090C (enExample) |
| AR (1) | AR039515A1 (enExample) |
| AT (2) | ATE427121T1 (enExample) |
| AU (2) | AU2003225256B2 (enExample) |
| BR (2) | BR0304660A (enExample) |
| CA (2) | CA2483910A1 (enExample) |
| CR (1) | CR7584A (enExample) |
| DE (2) | DE60334538D1 (enExample) |
| DK (2) | DK1549341T3 (enExample) |
| EC (2) | ECSP045468A (enExample) |
| ES (2) | ES2323056T3 (enExample) |
| HK (1) | HK1080372A1 (enExample) |
| IL (3) | IL164733A0 (enExample) |
| MX (2) | MXPA04010795A (enExample) |
| NO (2) | NO20035848L (enExample) |
| NZ (2) | NZ536242A (enExample) |
| PE (1) | PE20040597A1 (enExample) |
| PL (2) | PL373945A1 (enExample) |
| PT (2) | PT1549341E (enExample) |
| RS (2) | RS104504A (enExample) |
| RU (2) | RU2345789C2 (enExample) |
| TW (1) | TWI343388B (enExample) |
| UA (2) | UA81114C2 (enExample) |
| WO (2) | WO2003092602A2 (enExample) |
| ZA (2) | ZA200409692B (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE455852T1 (de) | 1999-06-02 | 2010-02-15 | Chugai Pharmaceutical Co Ltd | Neues hämopoietin rezeptorprotein nr10 |
| AU7445900A (en) * | 1999-09-27 | 2001-04-30 | Chugai Seiyaku Kabushiki Kaisha | Novel hemopoietin receptor protein, nr12 |
| AU2001296305B2 (en) | 2000-09-26 | 2007-12-06 | Duke University | RNA aptamers and methods for identifying the same |
| US7579000B2 (en) | 2002-05-01 | 2009-08-25 | Bayer Schering Pharma Ag | Tissue factor targeted antibodies as anticoagulants |
| BR0304660A (pt) * | 2002-05-01 | 2005-06-07 | Schering Ag | Anticorpos direcionados a fator de tecido como anticoagulantes |
| CA2490280A1 (en) | 2002-07-01 | 2004-01-08 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
| US7425328B2 (en) | 2003-04-22 | 2008-09-16 | Purdue Pharma L.P. | Tissue factor antibodies and uses thereof |
| US7833978B2 (en) * | 2004-02-20 | 2010-11-16 | Emory University | Thrombomodulin derivatives and conjugates |
| CN103045601B (zh) | 2004-04-22 | 2015-04-01 | 雷加多生物科学公司 | 改良的凝血因子调节物 |
| EP1889908A4 (en) | 2005-06-03 | 2012-04-25 | Mochida Pharm Co Ltd | PROTEIN FUSED WITH ANTI-CD14 ANTIBODY |
| WO2008039206A2 (en) * | 2005-10-05 | 2008-04-03 | The Trustees Of The University Of Pennsylvania | Fusion proteins for inhibition and dissolution of coagulation |
| US20110040073A1 (en) * | 2006-04-07 | 2011-02-17 | Novo Nordisk Healthcare A/G | Covalent Factor VII-Tissue Factor Complex |
| PE20080333A1 (es) | 2006-06-08 | 2008-06-15 | Chugai Pharmaceutical Co Ltd | Agentes para prevenir o tratar enfermedades inflamatorias |
| CN101522206B (zh) * | 2006-10-06 | 2013-03-27 | 旭化成制药株式会社 | 弥散性血管内凝血综合征的治疗剂和/或改善剂 |
| EP2129473B1 (en) | 2007-03-28 | 2019-07-03 | Medtronic ATS Medical, Inc. | Method for inhibiting platelet interaction with biomaterial surfaces |
| AU2008300516A1 (en) * | 2007-09-20 | 2009-03-26 | Bracco Imaging Spa | Method for the preparation of new oligoclonal antibodies |
| MY162546A (en) | 2007-12-05 | 2017-06-15 | Chugai Pharmaceutical Co Ltd | Therapeutic agent for pruritus |
| WO2009086552A1 (en) * | 2008-01-02 | 2009-07-09 | The Trustees Of The University Of Pennsylvania | Targeting recombinant therapeutics to circulating red blood cells |
| UA112050C2 (uk) * | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi) |
| JP5529869B2 (ja) * | 2008-08-14 | 2014-06-25 | メルク・シャープ・アンド・ドーム・コーポレーション | プロテインａアフィニティークロマトグラフィーを用いる抗体の精製方法 |
| WO2010045518A1 (en) * | 2008-10-16 | 2010-04-22 | The Trustees Of The University Of Pennsylvania | Compositions containing thrombomodulin domains and uses thereof |
| US20120165244A1 (en) * | 2008-10-30 | 2012-06-28 | Hua-Lin Wu | Methods for binding lewis y antigen |
| UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
| EP2230251A1 (en) * | 2009-03-19 | 2010-09-22 | Bracco Imaging S.p.A | Antibodies specifically active in the coronary plaque and method for their identification |
| WO2011026000A1 (en) * | 2009-08-28 | 2011-03-03 | Bayer Healthcare Llc | Cofactors for thrombin activation of factor vii and uses thereof |
| GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
| WO2011152694A2 (en) | 2010-06-04 | 2011-12-08 | Sk Chemicals Co., Ltd. | Fusion protein having factor vii activity |
| SMT201700547T1 (it) | 2010-06-15 | 2018-01-11 | Genmab As | Coniugati di farmaco anticorpo umano contro il fattore tissutale |
| JP6234224B2 (ja) | 2010-08-05 | 2017-11-22 | カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ | 血栓溶解及び抗凝固特性を有するタンパク質融合構築物 |
| RU2445365C1 (ru) * | 2010-11-03 | 2012-03-20 | Общество с ограниченной ответственностью "Инновационный Центр "Новые Технологии и Материалы" (ООО "ИЦ Новтехмат") | Штамм гибридных культивируемых клеток mus musculus - продуцент моноклональных антител, специфичных к протеину с человека (варианты) |
| WO2016167263A1 (ja) | 2015-04-14 | 2016-10-20 | 中外製薬株式会社 | Ｉｌ－３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物 |
| ES3036076T3 (en) | 2015-04-14 | 2025-09-12 | Chugai Pharmaceutical Co Ltd | Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient |
| WO2016176440A2 (en) * | 2015-04-28 | 2016-11-03 | Saint Louis University | Thrombin-thrombomodulin fusion proteins as protein c activators |
| WO2017189943A1 (en) * | 2016-04-28 | 2017-11-02 | Saint Louis University | Thrombin-thrombomodulin fusion proteins as a powerful anticoagulant |
| BR112019010034A2 (pt) * | 2016-11-16 | 2019-09-03 | Bayer Healthcare Llc | fator viii alvejado de hemácia e método de uso do mesmo |
| BR102017005783A2 (pt) * | 2017-03-21 | 2018-10-02 | Fund Butantan | processo de obtenção de esculptina e seus fragmentos, esculptina recombinante e seus usos |
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| UA130009C2 (uk) | 2018-05-07 | 2025-10-15 | Генмаб А/С | Спосіб лікування раку за допомогою комбінації антитіла до pd-1 і кон'югата антитіла до тканинного фактора і лікарського засобу |
| WO2020070237A1 (en) * | 2018-10-04 | 2020-04-09 | Thrombosis And Coagulation Ab | Method for the determination of protein s levels |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| BR112022006590A2 (pt) | 2019-11-20 | 2022-06-28 | Chugai Pharmaceutical Co Ltd | Preparação contendo anticorpos |
| CN114686444B (zh) * | 2020-12-31 | 2024-05-31 | 广州万孚生物技术股份有限公司 | 杂交瘤细胞、抗血栓调节蛋白单克隆抗体及其制备方法和应用 |
| CN114686443B (zh) * | 2020-12-31 | 2023-11-03 | 广州万孚生物技术股份有限公司 | 杂交瘤细胞、抗血栓调节蛋白单克隆抗体及其制备方法和应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4208479A (en) | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
| ZA862768B (en) * | 1985-04-17 | 1986-12-30 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| US5589173A (en) | 1986-11-04 | 1996-12-31 | Genentech, Inc. | Method and therapeutic compositions for the treatment of myocardial infarction |
| US5223427A (en) * | 1987-03-31 | 1993-06-29 | The Scripps Research Institute | Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain |
| US5437864A (en) * | 1987-03-31 | 1995-08-01 | The Scripps Research Institute | Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor |
| US4912207A (en) | 1987-05-06 | 1990-03-27 | Washington University | DNA clone of human thrombomodulin and portions thereof |
| DK299087D0 (da) | 1987-06-12 | 1987-06-12 | Novo Industri As | Proteins and derivatives thereof |
| US5298599A (en) * | 1988-12-30 | 1994-03-29 | Oklahoma Medical Research Foundation | Expression and purification of recombinant soluble tissue factor |
| EP0458903A4 (en) * | 1989-02-17 | 1992-06-17 | Codon | Soluble analogs of thrombomodulin |
| US6063763A (en) | 1989-04-28 | 2000-05-16 | Schering Aktiengesellschaft | Protease-resistant thrombomodulin analogs |
| US5466668A (en) | 1989-04-28 | 1995-11-14 | Schering Aktiengesellschaft | Superior thrombomodulin analogs for pharmaceutical use |
| US5256770A (en) | 1990-04-09 | 1993-10-26 | Schering Ag | Oxidation resistant thrombomodulin analogs |
| KR930008093B1 (ko) | 1990-08-03 | 1993-08-25 | 아사히가세이고오교 가부시끼가이샤 | 신규 폴리펩티드 및 이를 유효성분으로 하는 의약조성물 |
| US5506134A (en) * | 1990-10-22 | 1996-04-09 | Corvas International, Inc. | Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex |
| US5843442A (en) * | 1990-10-22 | 1998-12-01 | Corvas International, Inc. | Blood coagulation protein antagonists and uses therefor |
| JPH0578397A (ja) * | 1991-01-29 | 1993-03-30 | Sumitomo Pharmaceut Co Ltd | 血栓溶解タンパク質 |
| JPH06133780A (ja) * | 1992-10-23 | 1994-05-17 | Sumitomo Pharmaceut Co Ltd | 新規なｔ−ＰＡ改変体 |
| US5916874A (en) | 1994-04-20 | 1999-06-29 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for treating liver injury |
| US5736364A (en) * | 1995-12-04 | 1998-04-07 | Genentech, Inc. | Factor viia inhibitors |
| US5986065A (en) | 1997-03-10 | 1999-11-16 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
| JP3998419B2 (ja) * | 1998-04-03 | 2007-10-24 | 中外製薬株式会社 | ヒト組織因子（ｔｆ）に対するヒト型化抗体およびヒト型化抗体の作製方法 |
| CA2402596A1 (en) * | 2000-03-16 | 2001-09-27 | Genentech, Inc. | Anti-tissue factor antibodies with enhanced anticoagulant potency |
| US6632791B1 (en) * | 2000-06-21 | 2003-10-14 | Schering Aktiengesellschaft | Thrombomodulin analogs for pharmaceutical use |
| TWI338009B (en) * | 2001-10-29 | 2011-03-01 | Genentech Inc | Antibodies for inhibiting blood coagulation and methods of use thereof |
| EP1978108A3 (en) | 2002-01-08 | 2009-01-07 | Siemens Healthcare Diagnostics GmbH | Single nucleotide polymorphisms predicting cardiovascular disease and medication efficacy |
| BR0304660A (pt) * | 2002-05-01 | 2005-06-07 | Schering Ag | Anticorpos direcionados a fator de tecido como anticoagulantes |
| US7579000B2 (en) * | 2002-05-01 | 2009-08-25 | Bayer Schering Pharma Ag | Tissue factor targeted antibodies as anticoagulants |
-
2003
- 2003-04-30 BR BR0304660-5A patent/BR0304660A/pt not_active IP Right Cessation
- 2003-04-30 BR BR0304659-1A patent/BR0304659A/pt not_active IP Right Cessation
- 2003-04-30 RU RU2004135306/13A patent/RU2345789C2/ru not_active IP Right Cessation
- 2003-04-30 ES ES03721974T patent/ES2323056T3/es not_active Expired - Lifetime
- 2003-04-30 AR ARP030101529A patent/AR039515A1/es active IP Right Grant
- 2003-04-30 DK DK03721974T patent/DK1549341T3/da active
- 2003-04-30 RU RU2004135308/15A patent/RU2320366C2/ru not_active IP Right Cessation
- 2003-04-30 EP EP03721974A patent/EP1549341B1/en not_active Expired - Lifetime
- 2003-04-30 JP JP2004500787A patent/JP4567437B2/ja not_active Expired - Fee Related
- 2003-04-30 TW TW092110159A patent/TWI343388B/zh not_active IP Right Cessation
- 2003-04-30 PT PT03721974T patent/PT1549341E/pt unknown
- 2003-04-30 AT AT03721974T patent/ATE427121T1/de active
- 2003-04-30 CN CNB038157020A patent/CN100412090C/zh not_active Expired - Fee Related
- 2003-04-30 UA UA20041109787A patent/UA81114C2/uk unknown
- 2003-04-30 MX MXPA04010795A patent/MXPA04010795A/es active IP Right Grant
- 2003-04-30 DK DK03721975.5T patent/DK1503785T3/da active
- 2003-04-30 AU AU2003225256A patent/AU2003225256B2/en not_active Ceased
- 2003-04-30 PE PE2003000426A patent/PE20040597A1/es not_active Application Discontinuation
- 2003-04-30 AT AT03721975T patent/ATE484524T1/de active
- 2003-04-30 NZ NZ536242A patent/NZ536242A/en unknown
- 2003-04-30 RS YUP-1045/04A patent/RS104504A/sr unknown
- 2003-04-30 WO PCT/US2003/013522 patent/WO2003092602A2/en not_active Ceased
- 2003-04-30 DE DE60334538T patent/DE60334538D1/de not_active Expired - Lifetime
- 2003-04-30 UA UA20041109788A patent/UA85996C2/ru unknown
- 2003-04-30 CA CA002483910A patent/CA2483910A1/en not_active Abandoned
- 2003-04-30 HK HK06100300.9A patent/HK1080372A1/zh unknown
- 2003-04-30 NZ NZ536243A patent/NZ536243A/en unknown
- 2003-04-30 PT PT03721975T patent/PT1503785E/pt unknown
- 2003-04-30 AU AU2003225255A patent/AU2003225255B2/en not_active Ceased
- 2003-04-30 CN CNB038157039A patent/CN100563709C/zh not_active Expired - Fee Related
- 2003-04-30 IL IL16473303A patent/IL164733A0/xx unknown
- 2003-04-30 RS YU102404A patent/RS102404A/sr unknown
- 2003-04-30 CA CA002483909A patent/CA2483909A1/en not_active Abandoned
- 2003-04-30 EP EP03721975A patent/EP1503785B1/en not_active Expired - Lifetime
- 2003-04-30 US US10/427,805 patent/US7250168B2/en not_active Expired - Fee Related
- 2003-04-30 MX MXPA04010851A patent/MXPA04010851A/es active IP Right Grant
- 2003-04-30 KR KR1020047017456A patent/KR101013697B1/ko not_active Expired - Fee Related
- 2003-04-30 PL PL03373945A patent/PL373945A1/xx not_active Application Discontinuation
- 2003-04-30 PL PL373960A patent/PL210582B1/pl not_active IP Right Cessation
- 2003-04-30 KR KR1020047017458A patent/KR101080587B1/ko not_active Expired - Fee Related
- 2003-04-30 JP JP2004501558A patent/JP4460443B2/ja not_active Expired - Fee Related
- 2003-04-30 WO PCT/US2003/013521 patent/WO2003093422A2/en not_active Ceased
- 2003-04-30 ES ES03721975T patent/ES2354419T3/es not_active Expired - Lifetime
- 2003-04-30 DE DE60326970T patent/DE60326970D1/de not_active Expired - Lifetime
- 2003-12-30 NO NO20035848A patent/NO20035848L/no not_active Application Discontinuation
- 2003-12-30 NO NO20035849A patent/NO20035849L/no not_active Application Discontinuation
-
2004
- 2004-10-20 IL IL164733A patent/IL164733A/en not_active IP Right Cessation
- 2004-10-20 IL IL16473204A patent/IL164732A0/xx unknown
- 2004-11-24 CR CR7584A patent/CR7584A/es not_active Application Discontinuation
- 2004-11-30 ZA ZA200409692A patent/ZA200409692B/xx unknown
- 2004-11-30 ZA ZA200409694A patent/ZA200409694B/en unknown
- 2004-11-30 EC EC2004005468A patent/ECSP045468A/es unknown
- 2004-11-30 EC EC2004005467A patent/ECSP045467A/es unknown
-
2007
- 2007-06-21 US US11/766,155 patent/US7622457B2/en not_active Expired - Fee Related
- 2007-06-21 US US11/766,160 patent/US7622122B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005538046A5 (enExample) | ||
| RU2004135308A (ru) | Новые слитые белки тромбомодулина, обеспечивающие направленный перенос к тканевому фактору, в качестве антикоагулянтов | |
| JP2005532045A5 (enExample) | ||
| Weitz | New anticoagulant drugs | |
| Dulon et al. | Proteinase-activated receptor-2 and human lung epithelial cells: disarming by neutrophil serine proteinases | |
| US6451983B2 (en) | Tumor necrosis factor antibodies | |
| Waters et al. | Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein | |
| AU2014301041B2 (en) | Combination therapy using a Factor XII inhibitor and a C1-Inhibitor | |
| Abumiya et al. | An anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free-form TFPI but not lipoprotein-associated forms in plasma | |
| US20090317390A1 (en) | Novel tissue factor targeted antibodies as anticoagulants | |
| JP2003527861A5 (enExample) | ||
| US7049411B2 (en) | Human anti-factor IX/IXa antibodies | |
| Idell et al. | Fibrin turnover in lung inflammation and neoplasia | |
| JP2010504336A5 (enExample) | ||
| Takahashi et al. | Soluble thrombomodulin purified from human urine exhibits a potent anticoagulant effect in vitro and in vivo | |
| EP0668875A1 (en) | Clot directed anticoagulant, process for making same and methods of use | |
| EP1343823A2 (en) | Antithrombotic von willebrand factor (vwf) collagen bridging blockers | |
| Toschi et al. | Biochemistry and biology of hirudin | |
| Barbasz et al. | The assembly and activation of kinin-forming systems on the surface of human U-937 macrophage-like cells. | |
| Carrell et al. | Structural mobility of antithrombin and its modulation by heparin | |
| Naessens et al. | Elucidation of the epitope of a latency-inducing antibody: identification of a new molecular target for PAI-1 inhibition | |
| Tseng et al. | The effect of human C-reactive protein on the cell-attachment activity of fibronectin and laminin | |
| Dawes et al. | Conformational change in antithrombin induced by heparin, probed with a monoclonal antibody against the 1C/4B region | |
| EP1200562B1 (en) | Cell lines, ligands and antibody fragments for use in pharmaceutical compositions for preventing and treating haemostasis disorders | |
| KR960701649A (ko) | Xa인자 억제활성을 가진 신규 폴리펩티드 |